Royal College of Surgeons in Ireland
Browse
PMeverolimuscovid.pdf (340.1 kB)

Stick or twist: everolimus for seizures in tuberous sclerosis complex during the COVID-19 pandemic

Download (340.1 kB)
journal contribution
posted on 2022-09-02, 12:44 authored by Patrick MoloneyPatrick Moloney, Norman DelantyNorman Delanty

As the coronavirus disease 2019 (COVID-19) pandemic continues globally, protecting the health of vulnerable people with epilepsy (PWE) remains a priority. Many people with tuberous sclerosis complex (TSC) reside in long-term care facilities (LTCFs), which are high risk settings for infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and severe COVID-19 [1]. Pre-existing respiratory disease is associated with an increased risk of severe COVID-19, which may be relevant to those with lymphangioleiomyomatosis (LAM), a progressive cystic lung disease infrequently seen in women with TSC [2]

Funding

RCSI – Blackrock Clinic StAR MD programme, 2020

Novartis Irl.

History

Comments

The original article is available at https://www.sciencedirect.com/

Published Citation

Moloney PB, Delanty N. Stick or twist: everolimus for seizures in tuberous sclerosis complex during the COVID-19 pandemic. Seizure. 2021 ;91:271-272.

Publication Date

4 July 2021

PubMed ID

34252878

Department/Unit

  • FutureNeuro Centre
  • Beaumont Hospital
  • School of Pharmacy and Biomolecular Sciences

Research Area

  • Neurological and Psychiatric Disorders

Publisher

Elsevier BV

Version

  • Accepted Version (Postprint)